LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. [ Read More ]
The intrinsic value of one LIVN stock under the Base Case scenario is 81.29 USD. Compared to the current market price of 52.88 USD, LivaNova PLC is Undervalued by 35%.
Whether you're assessing long-term stability or short-term opportunities, Historical Valuation serves as a vital tool to enhance your investment approach, enabling you to make more informed investment decisions.
Sign up to access LivaNova PLC's intrinsic value history.
No restrictions, no limits.
All stocks, all tools.
Look for stocks that have been historically overvalued but are now trading below their intrinsic value.
Avoid stocks that are always undervalued and never reach their intrinsic value.
Find stocks that have historically corrected quickly from being undervalued to reaching their intrinsic value.
There are two methods to calculate the Intrinsic Value of a stock: DCF Valuation and Relative Valuation. We take the average of these two methods to estimate the intrinsic value as accurately as possible. You can see the Intrinsic Value of a stock at the top of this page.
LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. The firm is focused on the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals and healthcare systems throughout the world. The firm operates through two segments: Cardiac Surgery and Neuromodulation. Its Cardiac Surgery Business Franchise (CS) is engaged in the development, production and sale of cardiac surgery products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and other accessories used for extracorporeal circulation, systems for autologous blood transfusion and blood washing. Its Neuromodulation Business Franchise designs develops and markets neuromodulation-based medical devices for the treatment of epilepsy and difficult-to-treat depression (DTD) and obstructive sleep apnea.